Systemic treatment of hepatocellular carcinoma

被引:37
作者
Ganne-Carrié, N [1 ]
Trinchet, JC [1 ]
机构
[1] Univ Paris 13, Assistance Publ Hop Paris, Serv Hepatol Gastroenterol, Hop Jean Verdier,UFR SMBH,UPRES EA 3904, F-93140 Bondy, France
关键词
hepatocellular carcinoma; cirrhosis; survival; randomized controlled trials; interferon; hormonotherapy; chemotherapy;
D O I
10.1097/01.meg.0000108280.74393.d0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The results of systemic treatments for hepatocellular carcinoma are currently disappointing. In patients with advanced disease, none of the tested treatments (particularly systemic chemotherapy or hormonal treatment, such as tamoxifen) demonstrated an unequivocal benefit in terms of survival, and the trials including the largest numbers of patients have constantly been negative. After successful treatment of a first tumour, the most promising adjuvant strategy seems to be the use of interferon to treat patients who have hepatitis C infection. Nevertheless, only a few small randomized controlled trials have been performed and this result should be confirmed. Methodological improvement of clinical trials is needed, as major bias has often hampered the interpretation of the results. As recommended at a recent international conference in Barcelona, the most reliable methods for assessing the clinical outcome of a treatment in hepatocellular carcinoma are large randomized trials that each include a control arm of untreated patients, with overall survival as the primary endpoint, and an intention-to-treat analysis. New therapeutic strategies should be developed. Drugs such as vitamin D or vitamin A derivatives and inhibitors of COX-2 or angiogenesis could have a favourable influence on tumour growth. Some of these drugs are currently being tested in preliminary studies or even large randomized trials. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 44 条
[1]  
BARBARE J, 2002, P AN M AM SOC CLIN, pA551
[2]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[3]   TREATMENT OF HEPATOCELLULAR-CARCINOMA WITH TAMOXIFEN - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL IN 120 PATIENTS [J].
CASTELLS, A ;
BRUIX, J ;
BRU, C ;
AYUSO, C ;
ROCA, M ;
BOIX, L ;
VILANA, R ;
RODES, J .
GASTROENTEROLOGY, 1995, 109 (03) :917-922
[4]   CONTROLLED TRIAL OF TAMOXIFEN IN PATIENTS WITH ADVANCED HEPATOCELLULAR-CARCINOMA [J].
CEREZO, FJM ;
TOMAS, A ;
DONOSO, L ;
ENRIQUEZ, J ;
GUARNER, C ;
BALANZO, J ;
NOGUERAS, AM ;
VILARDELL, F .
JOURNAL OF HEPATOLOGY, 1994, 20 (06) :702-706
[5]   High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial [J].
Chow, PKH ;
Tai, BC ;
Tan, CK ;
Machin, D ;
Win, KM ;
Johnson, PJ ;
Soo, KC .
HEPATOLOGY, 2002, 36 (05) :1221-1226
[6]  
De Vos Irvine H, 1998, Lancet, V351, P215
[7]  
Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4
[8]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[9]  
ELBA S, 1994, ITAL J GASTROENTEROL, V26, P66
[10]  
Gallo C, 1998, LANCET, V352, P17